CorMedix Inc.

CorMedix Inc.

$11.63
0.41 (3.65%)
NASDAQ Global Market
USD, US
Biotechnology

CRMD Price Chart

Basic
Market Cap$499.37M
Price$11.63
52 Week Range2.89-13.85
Beta1.58
Margins
Gross Profit Margin83.54%
Operating Profit Margin-405.54%
Net Profit Margin-367.24%
Valuation (TTM)
P/E Ratio-15.08
Price to Sales Ratio57.12
Price to Book Ratio11.85
PEG Ratio-1.17

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

82

IPO Date

2010-05-13T00:00:00.000Z

Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Phone

908 517 9500

Address

300 Connell Drive, Berkeley Heights, NJ, 07922, US

CIK

0001410098